Economic value of vaccinating geographically hard-to-reach populations with measles vaccine: A modeling application in Kenya

Details

• Alternative Title:
  Vaccine
• Personal Author:
  Lee, Bruce Y. ; Brown, Shawn T. ; Haidari, Leila A. ; Clark, Samantha ; Abimbola, Taiwo ; Pallas, Sarah E. ; Wallace, Aaron S. ; Mitgang, Elizabeth A. ; Leonard, Jim ; Bartsch, Sarah M. ; Yemeke, Tatenda T. ; Zenkov, Eli ; Ozawa, Sachiko
• Description:
  Background:
  
  Since special efforts are necessary to vaccinate people living far from fixed vaccination posts, decision makers are interested in knowing the economic value of such efforts.
  
  Methods:
  
  Using our immunization geospatial information system platform and a measles compartment model, we quantified the health and economic value of a 2-dose measles immunization outreach strategy for children <24 months of age in Kenya who are geographically hard-to-reach (i.e., those living outside a specified catchment radius from fixed vaccination posts, which served as a proxy for access to services).
  
  Findings:
  
  When geographically hard-to-reach children were not vaccinated, there were 1427 total measles cases from 2016 to 2020, resulting in $9.5 million ($3.1–$18.1 million) in direct medical costs and productivity losses and 7504 (3338–12,903) disability-adjusted life years (DALYs). The outreach strategy cost $76 ($23–$142)/DALY averted (compared to no outreach) when 25% of geographically hard-to-reach children received MCV1, $122 ($40–$226)/DALY averted when 50% received MCV1, and $274 ($123–$478)/DALY averted when 100% received MCV1.
  
  Conclusion:
  
  Outreach vaccination among geographically hard-to-reach populations was highly cost-effective in a wide variety of scenarios, offering support for investment in an effective outreach vaccination strategy.
  
  
• Subjects:
  Cost-Benefit Analysis Geography, Medical Humans Kenya Measles Measles Vaccine Models, Theoretical Population Surveillance Risk Factors Vaccination
• Keywords:
  Economic Hard-to-reach Populations
• Source:
  Vaccine. 37(17):2377-2386
• Pubmed ID:
  30922700
• Pubmed Central ID:
  PMC6487493
• Document Type:
  Journal Article
• Funding:
  U24 GM110707/GM/NIGMS NIH HHSUnited States/ ; CC999999/ImCDC/Intramural CDC HHSUnited States/ ; U54 HD070725/HD/NICHD NIH HHSUnited States/ ; R01 HS023317/HS/AHRQ HHSUnited States/ ; U01 HD086861/HD/NICHD NIH HHSUnited States/ ; T32 CA009168/CA/NCI NIH HHSUnited States/
• Volume:
  37
• Issue:
  17
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:beda38d6e7c6d73fef178dba0104a79e362eb86c7928042086eaf18e1ac8b58200817a7d25c1a6ae3ecadfaf2772cc2f40e981c24c6e6440f71be3ad0b7ada0e
• Download URL:
  https://stacks.cdc.gov/view/cdc/78275/cdc_78275_DS1.pdf
• File Type:
  [PDF - 598.90 KB ]